Self Study Module 2 - Dry AMD: The Future of Therapy

Launch Date:
March 22, 2022
Expiration Date:
The accreditation for this activity has expired.
Return to Enrollment Page

Primary Audience:

Optometrists

Relevant Terms:

Dry AMD, Geographic Atrophy, Retina

OVERVIEW

By learning the dynamics of the biologic pathways that mediate GA clinicians may better understand the targets of various investigative therapies. Delve into the particulars of the complement system & learn about pipeline therapies under investigation for the treatment of GA!

FACULTY

Roger A. Goldberg, MD, MBA​

Vitreoretinal Specialist​
Bay Area Retina Associates​
Walnut Creek, CA​
Volunteer Faculty​
California Pacific Medical Center​
Ophthalmology Residency​
San Francisco, CA

LEARNING OBJECTIVES

1.
Describe disease detection and factors influencing progression​  
2.
Discuss the prevalence of age-related macular degeneration​
3.
Review the therapeutic interventions that have been explored as well as those in the pipeline  ​
4.
Understand the pathogenesis of GA​  

GENERAL INFORMATION

Geographic Atrophy: What to Look for and When to Refer
 
Supported by an unrestricted educational grant from Apellis.
 

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sponsored by​​ ​​ 

Evolve Medical Education LLC (Evolve) is a COPE accredited administrator. This activity, COPE Activity Number 123440, is accredited by COPE for continuing education for optometrists for 2 hours.

Course #: 76934-TD
Activity #: 123440

Credits and certificates received after completion of Final Assessment.​

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Roger A. Goldberg, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Aerie Pharmaceuticals, Allergan, Apellis, Carl Zeiss Meditec, Chengdu, Genentech, Graybug Vision, Neurotech, Novartis, Ribomics, and Santen. Speaker’s Bureau: Allergan, and Genentech.

The Evolve staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

 

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis.